What are the newest treatments for Liver Cancer in 2026

Newest Treatments for Liver Cancer in 2026

Based on the most current NCCN Guidelines (Version 2.2025), here's what you need to know about the latest treatment approaches for hepatocellular carcinoma (HCC):

First-Line Systemic Therapies (Preferred Options)

The most exciting advances involve immunotherapy combinations—treatments that help your immune system recognize and attack cancer cells:

Atezolizumab + Bevacizumab (Preferred)

This combination represents a major breakthrough. According to NCCN Guidelines, atezolizumab plus bevacizumab is now a preferred first-line option for unresectable HCC. Here's how it works:

• Atezolizumab is an immunotherapy (checkpoint inhibitor) that removes the "brakes" cancer uses to hide from your immune system
• Bevacizumab is an anti-angiogenic drug that cuts off blood supply to tumors
• The IMbrave150 trial showed this combination significantly improves survival compared to sorafenib (an older targeted therapy)

Tremelimumab + Durvalumab (Preferred)

This is another preferred first-line combination that's gaining traction:

• Both drugs work as immunotherapies through different mechanisms
• The HIMALAYA study showed five-year overall survival benefits
• This option is particularly useful for patients who may not tolerate other combinations

Other Recommended First-Line Options

According to NCCN Guidelines, these are also recommended:

• Durvalumab (single agent)
• Lenvatinib (targeted therapy)
• Sorafenib (still used, though older)
• Nivolumab + Ipilimumab (dual immunotherapy)
• Pembrolizumab (checkpoint inhibitor)

---

Second-Line Treatments (When Cancer Progresses)

If your cancer progresses on first-line therapy, NCCN Guidelines recommend:

Cabozantinib and Regorafenib

• These are tyrosine kinase inhibitors (drugs that block specific proteins cancer cells need to grow)
• Proven effective for patients whose disease worsened on sorafenib

Ramucirumab (Specific Situations)

• Recommended for patients with baseline AFP (alpha-fetoprotein) ≥400 ng/mL
• AFP is a tumor marker—elevated levels suggest more aggressive disease

Targeted Therapies for Specific Mutations

If your tumor has specific genetic changes, newer options include:

• Dostarlimab-gxly for MSI-H/dMMR tumors (specific genetic patterns)
• Selpercatinib for RET gene fusion-positive tumors
• Larotrectinib, entrectinib, repotrectinib for NTRK gene fusion-positive tumors

---

Locoregional Therapies (Local Treatments)

For patients not candidates for surgery, NCCN Guidelines emphasize these approaches:

Ablation (Radiofrequency/Microwave)

• Curative for tumors ≤3 cm in well-selected patients
• Destroys cancer with heat or cold

Arterially Directed Therapies

These deliver treatment directly to the tumor through blood vessels:

• TACE (Transarterial Chemoembolization) - chemotherapy delivered directly to tumor
• DEB-TACE (Drug-Eluting Bead TACE) - improved version with better drug delivery
• Radioembolization (Y-90) - radioactive microspheres that deliver radiation directly to tumor

Stereotactic Body Radiation Therapy (SBRT)

• Emerging as an alternative to ablation/embolization
• Delivers high-dose radiation precisely to tumors
• Useful for 1-3 tumors with minimal spread outside the liver

---

Adjuvant Therapy (After Surgery/Ablation)

New approaches to prevent recurrence after curative treatment:

Immunotherapy Options

• Nivolumab (perioperative - before and after surgery)
• Cemiplimab (neoadjuvant - before surgery)

Chemotherapy Approaches

• FOLFOX (hepatic arterial infusion) for tumors with microvascular invasion (cancer in small blood vessels)

---

Important Treatment Principles

According to NCCN Guidelines, all patients should be evaluated by a multidisciplinary team (surgeons, oncologists, radiologists, interventional radiologists) before treatment starts. This ensures you get the best approach for YOUR specific situation.

Key Factors Your Team Considers:

• Tumor size and location
• Liver function (how well your liver is working)
• Presence of cirrhosis (scarring)
• Spread beyond the liver (metastases)
• Genetic mutations in your tumor
• AFP levels (tumor marker)
• Your overall health

---

Questions to Ask Your Oncology Team

1. Which first-line treatment do you recommend for my specific stage and tumor characteristics?
2. Am I a candidate for curative therapies (surgery, transplant, ablation) or will I need systemic therapy?
3. Has my tumor been tested for genetic mutations (MSI-H, RET, NTRK) that might affect treatment options?
4. What is my baseline AFP level, and how will we monitor it during treatment?
5. Are there clinical trials available for my stage of disease?
6. If my cancer progresses on first-line therapy, what second-line options would you recommend?
7. What side effects should I expect, and how will we manage them?

---

Where to Learn More

• NCCN Guidelines for Hepatocellular Carcinoma (Version 2.2025) - the standard reference for HCC treatment
• American Cancer Society - patient-friendly HCC information
• National Cancer Institute (NCI) - clinical trial information and treatment summaries

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.